



June 24, 2015

The Honorable Doug Collins  
1504 Longworth House Office Building  
Washington, DC 20515

Dear Representative Collins,

On behalf of the Epilepsy Foundation, we want to thank you for your support on patent reform legislation as it pertains to protecting the current system for biopharmaceutical parties under Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA). Your comments in the Judiciary Committee are appreciated, as they would preserve both the Hatch-Waxman and BPCIA system so that early-stage research can gain the support necessary to advance through the drug development process.

The Epilepsy Foundation is the leading national voluntary health organization that speaks on behalf of more than 2.8 million Americans with epilepsy and seizures. We foster the wellbeing of children and adults affected by seizures through research programs, educational activities, advocacy, and direct services. Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Approximately 1 in 26 Americans will develop epilepsy at some point in their lifetime. For the majority of people living with epilepsy, anti-epilepsy drugs are the most common and most cost effective treatment for controlling and/or reducing seizures, and they must have meaningful and timely access to physician directed care.

Innovation is of particular importance to the nearly one million people living with epilepsy who don't have their seizures under control and are seeking new treatments and a cure, as well as many Americans living with complex chronic and rare conditions that are not appropriately managed with current treatment options. We are concerned that uncertainty and weak patent protections, if biopharmaceutical patents on approved medicines can be subject to challenges in multiple types of proceedings, even years after being on the market, it will be even more difficult to secure financing for therapeutic developments.

Any legislative reforms should maintain a strong and secure patent system that recognizes the rights of legitimate patent owners while addressing new forms of abuse that have emerged in both the courts as well as the (PTO), to foster an environment ripe for innovation and investment.

The Epilepsy Foundation thanks you for your support for patent reform that will accelerate the discovery and development of new therapies that individuals with epilepsy and many other complex chronic and rare conditions need to help them live their lives to the fullest potential. We urge you to continue to support amendments to patent legislation before it reaches the House floor that would preserve the Hatch-Waxman and BPCIA. Please do not hesitate to contact Angela Ostrom, Chief Operating Officer and Vice President Public Policy at 301-918-3766 or [aostrom@efa.org](mailto:aostrom@efa.org) with any questions.

Sincerely,

A handwritten signature in black ink that reads "Philip M. Gattone".

Philip M. Gattone, M.Ed.  
President & CEO  
Epilepsy Foundation



June 24, 2015

The Honorable Scott Peters  
1122 Longworth House Office Building  
Washington, DC 20515

Dear Representative Peters,

On behalf of the Epilepsy Foundation, we want to thank you for your support on patent reform legislation as it pertains to protecting the current system for biopharmaceutical parties under Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA). Your comments in the Judiciary Committee are appreciated, as they would preserve both the Hatch-Waxman and BPCIA system so that early-stage research can gain the support necessary to advance through the drug development process.

The Epilepsy Foundation is the leading national voluntary health organization that speaks on behalf of more than 2.8 million Americans with epilepsy and seizures. We foster the wellbeing of children and adults affected by seizures through research programs, educational activities, advocacy, and direct services. Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Approximately 1 in 26 Americans will develop epilepsy at some point in their lifetime. For the majority of people living with epilepsy, anti-epilepsy drugs are the most common and most cost effective treatment for controlling and/or reducing seizures, and they must have meaningful and timely access to physician directed care.

Innovation is of particular importance to the nearly one million people living with epilepsy who don't have their seizures under control and are seeking new treatments and a cure, as well as many Americans living with complex chronic and rare conditions that are not appropriately managed with current treatment options. We are concerned that uncertainty and weak patent protections, if biopharmaceutical patents on approved medicines can be subject to challenges in multiple types of proceedings, even years after being on the market, it will be even more difficult to secure financing for therapeutic developments.

Any legislative reforms should maintain a strong and secure patent system that recognizes the rights of legitimate patent owners while addressing new forms of abuse that have emerged in both the courts as well as the (PTO), to foster an environment ripe for innovation and investment.

The Epilepsy Foundation thanks you for your support for patent reform that will accelerate the discovery and development of new therapies that individuals with epilepsy and many other complex chronic and rare conditions need to help them live their lives to the fullest potential. We urge you to continue to support amendments to patent legislation before it reaches the House floor that would preserve the Hatch-Waxman and BPCIA. Please do not hesitate to contact Angela Ostrom, Chief Operating Officer and Vice President Public Policy at 301-918-3766 or [aostrom@efa.org](mailto:aostrom@efa.org) with any questions.

Sincerely,

A handwritten signature in black ink that reads "Philip M. Gattone".

Philip M. Gattone, M.Ed.  
President & CEO  
Epilepsy Foundation



June 24, 2015

The Honorable Mimi Walters  
236 Cannon House Office Building  
Washington, DC 20515

Dear Representative Walters,

On behalf of the Epilepsy Foundation, we want to thank you for your support on patent reform legislation as it pertains to protecting the current system for biopharmaceutical parties under Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA). Your comments in the Judiciary Committee are appreciated, as they would preserve both the Hatch-Waxman and BPCIA system so that early-stage research can gain the support necessary to advance through the drug development process.

The Epilepsy Foundation is the leading national voluntary health organization that speaks on behalf of more than 2.8 million Americans with epilepsy and seizures. We foster the wellbeing of children and adults affected by seizures through research programs, educational activities, advocacy, and direct services. Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Approximately 1 in 26 Americans will develop epilepsy at some point in their lifetime. For the majority of people living with epilepsy, anti-epilepsy drugs are the most common and most cost effective treatment for controlling and/or reducing seizures, and they must have meaningful and timely access to physician directed care.

Innovation is of particular importance to the nearly one million people living with epilepsy who don't have their seizures under control and are seeking new treatments and a cure, as well as many Americans living with complex chronic and rare conditions that are not appropriately managed with current treatment options. We are concerned that uncertainty and weak patent protections, if biopharmaceutical patents on approved medicines can be subject to challenges in multiple types of proceedings, even years after being on the market, it will be even more difficult to secure financing for therapeutic developments.

Any legislative reforms should maintain a strong and secure patent system that recognizes the rights of legitimate patent owners while addressing new forms of abuse that have emerged in both the courts as well as the (PTO), to foster an environment ripe for innovation and investment.

The Epilepsy Foundation thanks you for your support for patent reform that will accelerate the discovery and development of new therapies that individuals with epilepsy and many other complex chronic and rare conditions need to help them live their lives to the fullest potential. We urge you to continue to support amendments to patent legislation before it reaches the House floor that would preserve the Hatch-Waxman and BPCIA. Please do not hesitate to contact Angela Ostrom, Chief Operating Officer and Vice President Public Policy at 301-918-3766 or [aostrom@efa.org](mailto:aostrom@efa.org) with any questions.

Sincerely,

A handwritten signature in black ink that reads "Philip M. Gattone".

Philip M. Gattone, M.Ed.  
President & CEO  
Epilepsy Foundation



June 24, 2015

The Honorable Hank Johnson  
2240 Rayburn House Office Building  
Washington, DC 20515

Dear Representative Johnson,

On behalf of the Epilepsy Foundation, we want to thank you for your support on patent reform legislation as it pertains to protecting the current system for biopharmaceutical parties under Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA). Your comments in the Judiciary Committee are appreciated, as they would preserve both the Hatch-Waxman and BPCIA system so that early-stage research can gain the support necessary to advance through the drug development process.

The Epilepsy Foundation is the leading national voluntary health organization that speaks on behalf of more than 2.8 million Americans with epilepsy and seizures. We foster the wellbeing of children and adults affected by seizures through research programs, educational activities, advocacy, and direct services. Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Approximately 1 in 26 Americans will develop epilepsy at some point in their lifetime. For the majority of people living with epilepsy, anti-epilepsy drugs are the most common and most cost effective treatment for controlling and/or reducing seizures, and they must have meaningful and timely access to physician directed care.

Innovation is of particular importance to the nearly one million people living with epilepsy who don't have their seizures under control and are seeking new treatments and a cure, as well as many Americans living with complex chronic and rare conditions that are not appropriately managed with current treatment options. We are concerned that uncertainty and weak patent protections, if biopharmaceutical patents on approved medicines can be subject to challenges in multiple types of proceedings, even years after being on the market, it will be even more difficult to secure financing for therapeutic developments.

Any legislative reforms should maintain a strong and secure patent system that recognizes the rights of legitimate patent owners while addressing new forms of abuse that have emerged in both the courts as well as the (PTO), to foster an environment ripe for innovation and investment.

The Epilepsy Foundation thanks you for your support for patent reform that will accelerate the discovery and development of new therapies that individuals with epilepsy and many other complex chronic and rare conditions need to help them live their lives to the fullest potential. We urge you to continue to support amendments to patent legislation before it reaches the House floor that would preserve the Hatch-Waxman and BPCIA. Please do not hesitate to contact Angela Ostrom, Chief Operating Officer and Vice President Public Policy at 301-918-3766 or [aostrom@efa.org](mailto:aostrom@efa.org) with any questions.

Sincerely,

A handwritten signature in black ink that reads "Philip M. Gattone".

Philip M. Gattone, M.Ed.  
President & CEO  
Epilepsy Foundation